Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint

Journal of Psychiatric Research

Volumn 42, Issue 14, 2008, Pages 1176-1184

  Pollack, Mark H ^a   Kornstein, Susan G ^b   Spann, Melissa E ^c   Crits Christoph, Paul ^d   Raskin, Joel ^c   Russell, James M ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Duloxetine; Early improvement; Generalized anxiety disorder; Remission

Indexed keywords

DULOXETINE; PLACEBO;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE;

ADULT; ANXIETY DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME;

EID: 52449100180     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2008.02.002     Document Type: Article

References (35)

1. Albus M., Lecrubier Y., Maier W., et al. Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica 82 (1990) 359-365
2. Ballenger J.C. Clinical guidelines for establishing remission in patients with depression and anxiety. Journal of Clinical Psychiatry 60 (1999) 29-34
3. Ballenger J.C., Davidson J.R.T., Lecrubier Y., et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. Journal of Clinical Psychiatry 62 (2001) 53-58
4. Buist-Bouwman M.A., De Graaf R., Vollebergh W.A.M., et al. Functional disability of mental disorders and comparison with physical disorders: a study among the general population of six European countries. Acta Psychiatrica Scandinavica 113 (2006) 492
5. Bull S.A., Hunkeler E.M., Lee J.Y., et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Annals of Pharmacotherapy 36 (2002) 578-584
6. Chambless D.L., and Peterman M. Evidence on cognitive-behavioral therapy for generalized anxiety disorder and panic disorder: the second decade. In: Leahy R.L. (Ed). Contemporary cognitive therapy: theory, research, and practice (2004), Guilford Press, New York (NY, USA) 86-115
7. Downing R.W., and Rickels K. Early treatment response in anxious outpatients treated with diazepam. Acta Psychiatrica Scandinavica 72 (1985) 522-528
8. Goodman W.K., Bose A., and Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. Journal of Affective Disease 87 (2005) 161-167
9. Grant B.F., Hasin D.S., Stinson F.S., et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychological Medicine 35 (2005) 1747-1759
10. Guy W. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology (1976), Department of Health, Education and Welfare, Publication (ADM) 76-338, Washington (DC) 218-222
11. Hamilton M. The assessment of anxiety states by rating. British Journal of Psychiatry 32 (1959) 50-55
12. Hartford J., Kornstein S., Liebowitz M., et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. International Clinical Psychopharmacology 22 (2007) 167-174
13. Hoffman D.L., Dukes E.M., and Wittchen H.U. Human and economic burden of generalized anxiety disorder. Depression and Anxiety 25 (2008) 72-90
14. Kessler R.C., Chiu W.T., Demler O., et al. Prevalence, severity, and co-morbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 62 (2005) 617-627
15. Kessler R.C., Berglund P.A., Demler O., et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 62 (2005) 593-602
16. Koponen H., Allgulander C., Erickson J., et al. The efficacy of duloxetine for treatment of generalized anxiety disorder: implications for primary care physicians. Primary Care, Comparative Journal of Clinical Psychiatry 9 (2007) 100-107
17. Leon A.C., Olfson M., Portera L., Farber L., and Sheehan D.V. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. International Journal of Psychiatry in Medicine 27 (1997) 93-105
18. Lipman R.S., and Covi L. Outpatient treatment of neurotic depression: medication and group psychotherapy. In: Spitzer R., and Klein D. (Eds). Evaluation of psychological therapies (1976), John Hopkins University Press, Baltimore 178-218
19. Mitte K., Noak P., Steil R., et al. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. Journal of Clinical Psychopharmacology 25 (2005) 141-150
20. Nierenberg A.A., McLean N.E., Alpert J.E., et al. Early non-response to fluoxetine as a predictor of poor 8-week outcome. American Journal of Psychiatry 152 (1995) 1500-1503
21. Ninan P.T. Dissolving the burden of generalized anxiety disorder. Journal of Clinical Psychiatry 62 Suppl. 19 (2001) 5-10
22. Pollack M.H. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. Journal of Clinical Psychiatry 62 Suppl. 19 (2001) 20-25
23. Pollack M.H., Rapaport M.H., Fayyad R., et al. Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder. Journal of Psychiatric Research 36 (2002) 229-236
24. Raskin A., Schulterbrandt J., Reating N., et al. Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. Journal of Nervous and Mental Disease 148 (1969) 87-98
25. Rickels K., Rynn M., Iyengar M., et al. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. Journal of Clinical Psychiatry 67 (2006) 41-47
26. Rickles K., and Rynn M. Pharmacotherapy of generalized anxiety disorder. Journal of Clinical Psychiatry 63 (2002) 9-16
27. Riskind J.H., Beck A.T., Brown G., and Steer R.A. Taking the measure of anxiety and depression. Validity of the reconstructed Hamilton scales. Journal of Nervous and Mental Disease 175 (1987) 474-479
28. Rynn M., Khalid-Khan S., Garcia-Espana F., et al. Early response and 8-week treatment outcome in GAD. Depression and Anxiety 23 (2006) 461-465
29. Rynn MA, Russell JM, Erickson J, et al. Efficacy and safety of duloxetine in treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depression and Anxiety [Published Online: 20 February 2007].
30. Sackeim H.A., Roose S.P., and Lavori P.W. Determining the duration of antidepressant treatment: application of signal detection methodology and the need for adaptive designs (DAD). Biological Psychiatry 59 (2006) 483-492
31. Sheehan D.V., Harnett-Sheehan K., and Raj B.A. The measurement of disability. International Clinical Psychopharmacology 11 Suppl. 3 (1996) 89-95
32. Stassen H.H., Angst J., and Delini Stula A. Fluoxetine versus moclobemide cross-comparison between the time courses of improvement. Pharmacopsychiatry 32 (1999) 56-60
33. Wittchen H.U. Generalized anxiety disorder: prevalence, burden and cost to society. Depression and Anxiety 16 (2002) 162-171
34. Yonkers K.A., Bruce S.E., Dyck I.R., et al. Chronicity, relapse, and illness-course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depression and Anxiety 17 (2003) 173-179
35. Zigmond A.S., and Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 67 (1983) 361-370